On December 27, Gelonghui reported that Wuhan Hiteck Biological Pharma (300683.SZ) announced on the investor interaction platform that the company recently obtained the revised "Pharmaceutical Production License" from the Hubei Provincial Drug Administration, agreeing to the application for change of the "Pharmaceutical Production License". The new license added suppositories to the production scope, while other contents remain unchanged.
Due to the transfer of the suppository license number, the company’s "Pharmaceutical Production License" has added the production scope of suppository B. The above changes have no significant impact on the company's performance, and all investors are advised to invest rationally and pay attention to investment risks.
